CRISPR Therapeutics
CRSP
492 hedge funds and large institutions have $3.67B invested in CRISPR Therapeutics in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 175 increasing their positions, 117 reducing their positions, and 59 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 117
36% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 59
21% more call options, than puts
Call options by funds: $127M | Put options by funds: $105M
3% more funds holding
Funds holding: 480 → 492 (+12)
0.14% more ownership
Funds ownership: 80.24% → 80.38% (+0.14%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
9% less capital invested
Capital invested by funds: $4.01B → $3.67B (-$342M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$249M |
| 2 |
Two Sigma Investments
New York
|
+$53.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$41.8M |
| 4 |
Millennium Management
New York
|
+$18.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$248M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$40.2M |
| 3 |
Squarepoint
New York
|
-$22.5M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$21.8M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$14.5M |
CRSP Hedge Fund Activity: Q1 2026 in Review
492 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2026, worth a combined $3.67B — down 8.5% from $4.01B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new CRSP positions and 59 closed out — a net gain of 21 holders — while 175 added to existing stakes and 117 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $249M. The largest seller was Capital International Investors, cutting an estimated $248M.
- 492 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2026, up from 480 in Q4 2025.
- Funds reported $3.67B of CRISPR Therapeutics stock for Q1 2026, down 8.5% quarter-over-quarter.
- 80 funds opened new CRISPR Therapeutics positions in Q1 2026 and 59 closed out, a net change of +21 holders.
- The largest CRISPR Therapeutics buyer in Q1 2026 was Capital World Investors, an estimated $249M added.
- The largest CRISPR Therapeutics seller in Q1 2026 was Capital International Investors, an estimated $248M sold.
Based on aggregated 13F filings for Q1 2026.